Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

172 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Exposures associated with SARS-CoV-2 infection in France: A nationwide online case-control study.
Galmiche S, Charmet T, Schaeffer L, Paireau J, Grant R, Chény O, Von Platen C, Maurizot A, Blanc C, Dinis A, Martin S, Omar F, David C, Septfons A, Cauchemez S, Carrat F, Mailles A, Levy-Bruhl D, Fontanet A. Galmiche S, et al. Among authors: omar f. Lancet Reg Health Eur. 2021 Aug;7:100148. doi: 10.1016/j.lanepe.2021.100148. Epub 2021 Jun 7. Lancet Reg Health Eur. 2021. PMID: 34124709 Free PMC article.
Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France.
Charmet T, Schaeffer L, Grant R, Galmiche S, Chény O, Von Platen C, Maurizot A, Rogoff A, Omar F, David C, Septfons A, Cauchemez S, Gaymard A, Lina B, Lefrancois LH, Enouf V, van der Werf S, Mailles A, Levy-Bruhl D, Carrat F, Fontanet A. Charmet T, et al. Among authors: omar f. Lancet Reg Health Eur. 2021 Sep;8:100171. doi: 10.1016/j.lanepe.2021.100171. Epub 2021 Jul 13. Lancet Reg Health Eur. 2021. PMID: 34278372 Free PMC article.
Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France.
Grant R, Charmet T, Schaeffer L, Galmiche S, Madec Y, Von Platen C, Chény O, Omar F, David C, Rogoff A, Paireau J, Cauchemez S, Carrat F, Septfons A, Levy-Bruhl D, Mailles A, Fontanet A. Grant R, et al. Among authors: omar f. Lancet Reg Health Eur. 2022 Feb;13:100278. doi: 10.1016/j.lanepe.2021.100278. Epub 2021 Nov 26. Lancet Reg Health Eur. 2022. PMID: 34849500 Free PMC article.
SARS-CoV-2 incubation period across variants of concern, individual factors, and circumstances of infection in France: a case series analysis from the ComCor study.
Galmiche S, Cortier T, Charmet T, Schaeffer L, Chény O, von Platen C, Lévy A, Martin S, Omar F, David C, Mailles A, Carrat F, Cauchemez S, Fontanet A. Galmiche S, et al. Among authors: omar f. Lancet Microbe. 2023 Jun;4(6):e409-e417. doi: 10.1016/S2666-5247(23)00005-8. Epub 2023 Apr 18. Lancet Microbe. 2023. PMID: 37084751 Free PMC article.
Risk of SARS-CoV-2 Infection Among Households With Children in France, 2020-2022.
Galmiche S, Charmet T, Rakover A, Schaeffer L, Chény O, von Platen C, Omar F, David C, Mailles A, Carrat F, Fontanet A. Galmiche S, et al. Among authors: omar f. JAMA Netw Open. 2023 Sep 5;6(9):e2334084. doi: 10.1001/jamanetworkopen.2023.34084. JAMA Netw Open. 2023. PMID: 37713194 Free PMC article.
District-Level Forecast of Achieving Trachoma Elimination as a Public Health Problem By 2030: An Ensemble Modelling Approach.
Srivathsan A, Abdou A, Al-Khatib T, Apadinuwe SC, Badiane MD, Bucumi V, Chisenga T, Kabona G, Kabore M, Kanyi SK, Bella L, M'po N, Masika M, Minnih A, Sitoe HM, Mishra S, Olobio N, Omar FJ, Phiri I, Sanha S, Seife F, Sharma S, Tekeraoi R, Traore L, Watitu T, Bol YY, Borlase A, Deiner MS, Renneker KK, Hooper PJ, Emerson PM, Vasconcelos A, Arnold BF, Porco TC, Hollingsworth TD, Lietman TM, Blumberg S. Srivathsan A, et al. Among authors: omar fj. Clin Infect Dis. 2024 Apr 25;78(Supplement_2):S101-S107. doi: 10.1093/cid/ciae031. Clin Infect Dis. 2024. PMID: 38662700 Free PMC article.
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, Omar FL, Kee JJ, Bekker LG, Laher F, Naicker N, Jani I, Mgodi NM, Hunidzarira P, Sebe M, Miner MD, Polakowski L, Ramirez S, Nebergall M, Takuva S, Sikhosana L, Heptinstall J, Seaton KE, De Rosa S, Diazgranados CA, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, Tomaras GD, McElrath MJ, Corey L, Mngadi K, Goepfert P; HVTN 107 Protocol Team. Moodie Z, et al. Among authors: omar fl. PLoS Med. 2024 Mar 19;21(3):e1004360. doi: 10.1371/journal.pmed.1004360. eCollection 2024 Mar. PLoS Med. 2024. PMID: 38502656 Free PMC article. Clinical Trial.
172 results